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 ABSTRACT 
Atherosclerosis is a chronic systemic inflammatory disease of large and medium sized 
arteries, developing slowly and silently over decades. The disease is usually not 
apparent until occurrence of a sudden clinical symptom, such as myocardial infarction 
(MI) or stroke. Several classical risk factors have been established to play a role in the 
progression of disease over a long period of time. However, markers recognizing 
vulnerable patients being at risk of having an event in the near future are lacking. Thus, 
more knowledge about the ongoing complex pathogenesis is needed for identification 
of potential biomarkers and therapeutic targets of atherosclerosis. Patients with carotid 
atherosclerosis experiencing cerebral symptoms within one month before undergoing 
carotid endarterectomy (CEA) are classified having vulnerable plaques. 
 
Based on the classification above, I show in this thesis that mRNA levels of enzymes in 
the leukotriene 5-lipoxygenase pathway, 5-lipoxygenase (5-LO) and leukotriene A4 
hydrolase (LTA4H), are associated with plaque vulnerability.  
 
Gene expression can be investigated on a single target level using real-time PCR or by 
analyzing thousands of genes simultaneously, using global transcription microarrays. 
Based on correlations to microarrays we argue for using total RNA mass in 
normalization of real-time PCR data, when analyzing heterogeneous human specimen. 
 
To identify new candidates of plaque vulnerability an unbiased approach was used - 
transcript profiles of symptomatic plaques were compared to asymptomatic plaques, 
demonstrating an increase of fatty acid binding protein 4 (FABP4), which was 
associated with vulnerability, independent of age or gender. FABP4 localize mainly to 
the numerous macrophages present in the atherosclerotic plaque. This study suggests 
FABP4 to play a role in plaque vulnerability and to be a potential valuable biomarker 
within the carotid atherosclerotic plaque. 
 
To determine if any atherosclerosis-related changes can be detected in circulating cells 
the transcriptome of leukocytes in the circulation from an experimental atherosclerotic 
model Apoe
-/-
was analyzed. Surprisingly, we also here identify FABP4 as a marker in 
neutrophils and monocytes reflecting atherosclerotic lesion progression. Moreover, I 
observe human monocytes and neutrophils from the circulation to be positive for 
FABP4. Our findings make FABP4 in circulating cells interesting for functional 
investigations, and an appealing and easy accessible biomarker target for potential 
future translation into clinical purposes. 
  
In conclusion, I have studied inflammatory genes being involved in the pathogenic 
process during atherosclerosis using human and experimental models. In brief, we 
demonstrate that human vulnerable plaques display increased mRNA levels of 5-LO 
and LTA4H, and FABP4. In addition, the latter is shown in an experimental model, to 
be a potential valuable biomarker in circulating leukocytes reflecting the extent of 
atherosclerotic lesion. Our discoveries in the human plaque may be of future clinical 
relevance to identify vulnerable plaques, whereas FABP4 in leukocytes potentially 
could be useful for recognizing asymptomatic patients before onset of symptoms. 
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PREFACE 
Cardiovascular disease is the leading cause of death and disability in the world. 
Although a large proportion is preventable, the incidence continues to rise mainly 
because preventive measures are inadequate. The most common types of CVD, 
cerebrovascular disease and coronary artery disease, have severe consequences for 
the affected individual and results in huge costs for the society. The main underlying 
pathological process driving these diseases is atherosclerosis. Atherosclerosis derives 
from the Greek words, athere meaning gruel, and skleros meaning hard.  
Atherosclerosis was for decades believed to be just a passive accumulation of lipids 
within the arterial vessel. Today the disease is recognized to be far more complex, 
involving the interplay between locally infiltrated immune cells and lipids in the 
plaque, along with systemic inflammation. Although several classical risk factors have 
been identified, there is still a need for better screenings/markers/measures to find 
patients in high risk of cardiovascular events and ultimately prevent future events.  
 
This thesis focuses on identification of markers associated with plaque vulnerability 
and markers associated with atherosclerotic plaque progression, from initiation of fatty 
streaks to formed advanced plaques, which may cause clinical symptoms. Three out of 
the four included papers have been based on human carotid endarterectomies from our 
Biobank at Karolinska Endarterectomies (BiKE). In addition, experimental murine 
models have been used to study pre-chosen genes as well as to analyze disease 
progression over time. All my investigations have primarily been based on mRNA, 
using real-time PCR to study pre-selected genes, and microarray technology to analyze 
thousands of potential targets. In addition, I have localized the different proteins to the 
specific cell types. Some of the findings uncover potential involvement of markers in 
plaque vulnerability, while other illustrates potential biomarkers which may be of value 
for clinical screening of atherosclerotic lesion progression.   
 
In this thesis I will give an overview of the atherosclerotic disease process including a 
discussion about the vulnerable plaque and ways to identify it. Furthermore, I will 
discuss the main relevant cell types and targets for the studies included in this thesis 
and the importance of my findings. 
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1 INTRODUCTION 
1.1 ATHEROSCLEROSIS- AN OVERVIEW 
Atherosclerosis is a progressive systemic inflammatory disease of the arterial system, 
affecting large and medium sized arteries, and the main underlying cause of 
cardiovascular diseases (CVD), such as cerebrovascular disease or coronary artery 
disease (Hansson 2005). Despite advances in risk factor management, CVD is the 
leading cause of mortality worldwide accounting for around 17.3 million victims 2008, 
which represents 30% of all global deaths according to World Health Organization 
(WHO). Of these deaths approximately 6.2 million were due to stroke and 7.3 million 
due to coronary heart disease (WHO). If the current trend continues, this number is 
predicted to increase to approximately 25 million deaths by 2020 (Dahlöf 2010; Lloyd-
Jones 2010). 
 
Epidemiological studies have established several risk factors for CVD of which the 
most important are hypertension, hypercholesterolemia, smoking and diabetes (Dahlöf 
2010) (Mehta, Saldeen et al. 1998). Despite these known risk factors, there is a great 
need to identify additional markers to improve identification of patients at high risk 
before onset of symptoms (Eagle, Ginsburg et al. 2010). Although several 
inflammatory mediators, such as soluble CD40 ligand (sCD40L), adiponectin, C-
reactive protein (CRP) and matrix metalloproteinase 9 (MMP-9), associate with 
increased cardiovascular risks, they only rarely add to the risk score models available 
(Packard and Libby 2008). One exception is CRP although it is being under debate of 
its potential utility (Libby and Ridker 2004; Scirica and Morrow 2006). In addition, 
several other markers are being thoroughly investigated in large patient cohort studies. 
 
A healthy vessel wall consists of three different layers: intima, media and adventitia. 
The innermost layer, the intima, is composed of endothelial cells facing the lumen of 
the vessel, as well as some loose connective tissue and occasional smooth muscle cells 
(SMC) and macrophages. The middle layer, the media, is of importance for 
contractility of the vessel and consists almost solely of smooth muscle cells. The outer 
layer, the adventitia, is composed of  SMCs, fibroblasts, connective tissue, immune 
cells and vasa vasora, which supply the vessel with oxygen and nutrients. Between all 
the three different layers elastic laminae are present. It is within the intima of large and 
medium sized arteries that atherosclerotic lesions, also called plaques, are formed 
(Lusis 2000), a process referred to as atherogenesis. 
 
Historically atherosclerosis was thought to develop due to passive accumulation of 
lipids in the vessel wall (Brown and Goldstein 1983). Another theory dominating the 
scene was the response to injury hypothesis, explaining lesion development as a cause 
of migrating and proliferating smooth muscle cells upon endothelial damage (Ross 
1976). However, the picture changed in the mid-eighties, when active immune cells 
were demonstrated to be present within the plaque (Jonasson, Holm et al. 1986) and 
today atherosclerosis is considered to be a chronic inflammatory systemic disease 
(Hansson and Hermansson 2011). 
 
 
   3 
1.1.1 Atherogenesis 
Formation of fatty streaks starts to form when low density lipoprotein (LDL) particles 
present in the circulation diffuse into the intimal layer of the vessel or are transported 
through the endothelial cell layer of arteries (von Eckardstein and Rohrer 2009). The 
LDL particle carries the large protein ApoB100 which is negatively charged and 
interacts with positively charged proteoglycans present in the extracellular matrix. This 
step has been shown to be important in initiating early atherosclerosis (Skalen, 
Gustafsson et al. 2002; Tabas, Williams et al. 2007). 
 
Once in the subendothelial space, the LDL particles are trapped and prone to undergo 
oxidative modifications by enzymatic attacks by lipoxygenases and myeloperoxidases, 
or by reactive oxygen species (Berliner and Heineke 1996) (Figure 1). As a result of the 
oxidation, the modified components (e.g. truncated lipids and reactive aldehydes) will 
activate endothelial cells and macrophages to express adhesion molecules (Cybulsky 
and Gimbrone 1991; Nakashima, Raines et al. 1998) and chemokines (Zernecke and 
Weber 2010). In addition to the modified LDL, sheer stress at arterial branching points 
is believed to cause further activation and lead to expression of selectins on the 
endothelial wall, in turn initiating leukocyte migration into the vessel wall (Eriksson, 
Xie et al. 2001). 
 
 
 
 
 
 
Figure 1. The plaque has a core of lipids, including cholesterol, living and apoptotic cells and a fibrous 
cap with smooth muscle cells and collagen. Plasma lipoproteins accumulate in the subendothelial 
region. Several types of cells of the immune response are present throughout the atheroma including 
macrophages, T cells, mast cells and DCs. The atheroma builds up in the intima, the innermost layer of 
the artery. Outside the intima, the media contains smooth muscle cells, and further abluminally, the 
adventitia continues into the surrounding connective tissue. Here, immune cells accumulate outside the 
advanced atheroma and may develop into tertiary lymphoid structures with germinal centers. Reprinted 
by permission from Macmillian Publishers Ltd: Nature Immunology, Hansson et al. 2011 
Mar;12(3):204-12. Copyright 2012. 
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Infiltrating monocytes are further stimulated and differentiate into macrophages 
essential for lesion development (Smith, Trogan et al. 1995). The oxidation of LDL 
present in the intima will increase its binding to scavenger receptors, especially CD36 
and SR-A1, on the macrophages. The increased endocytosis of cholesterol eventually 
turns these macrophages into foam cells, which eventually will die and form the 
necrotic core (Goldstein, Ho et al. 1979; Kunjathoor, Febbraio et al. 2002).  
 
Besides monocytes, several other different cell types including T cells, B cells, mast 
cells, neutrophils and dendritic cells, are present within the lesion (Hansson and 
Hermansson 2011). The plaque eventually becomes more and more complex, 
containing a lot of necrotic and apoptotic cells constituting the necrotic core, which is 
covered by a cap separating the lesion from the blood stream.  
 
1.1.2 The plaque  
Studies have shown that acute clinical manifestations of atherosclerotic disease, such as 
myocardial infarction (MI) or stroke, are mainly a consequence of acute disruption, 
rupture or erosion of the plaque. The rupture leads to exposure of thrombogenic plaque 
components to the bloodstream with subsequent thrombus formation. The newly 
formed thrombus may occlude the whole lumen, giving rise to MI, or cause distal 
embolization as seen in symptomatic atherosclerotic carotid disease (Spagnoli, 
Mauriello et al. 2004). In addition, it has been shown that the coronary plaque 
phenotype in patients with coronary artery disease (CAD) significantly correlate with 
the carotid plaque composition (Zhao, Zhao et al. 2011). Thus, presumably 
investigations of lesions at one site in the vasculature, as the carotid lesion in our 
studies, reflect lesion phenotype at other sites. 
 
Histology of plaques obtained during endarterectomy or post-mortem has associated 
certain lesion characteristics with adverse clinical events. These plaques are referred to 
as unstable, vulnerable or high-risk plaques and defined as plaques with a high risk to 
cause local thrombosis with unstable clinical symptoms such as MI, unstable angina or 
cerebrovascular events (Schaar, Muller et al. 2004). The most common plaque 
phenotype, the classically defined vulnerable plaque will be described in more detail in 
coming section. However, it is important to stress that these rupture-prone plaques are 
not the only vulnerable plaques. All types of atherosclerotic plaques with high 
likelihood of thrombotic complications and progression should be considered as 
vulnerable plaques. Basically, there are three types of vulnerable plaques: 
 
1) Classical plaques prone to rupture  
2) Plaques with superficial erosion (Farb, Burke et al. 1996) 
3) Plaques with calcified nodules protruding the lumen (Virmani, Kolodgie et al. 2000). 
 
The mechanism to which carotid atherosclerosis results in cerebrovascular symptoms 
are less understood than those linking coronary disease and MI. Plaque erosion, 
which is common in the coronaries, was only recently described in carotid lesions and 
shown to be present in 10% of patients with strokes or TIA (Spagnoli, Mauriello et al. 
2004). Finally, plaques with calcified nodules are least well understood and represent 
the least common cause of luminal thrombus, accounting for 2-5% of coronary 
thrombi (Virmani, Kolodgie et al. 2000). 
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The lesion itself may be of stenotic or non-stenotic nature. However, non-stenotic 
plaques are far more frequent throughout the arterial tree and also the majority of 
plaques causing MI (Ambrose, Tannenbaum et al. 1988).  
 
1.1.3 The classical vulnerable plaque 
The main three features of the classically defined vulnerable plaque are: 
 
 Large lipid core 
 Thin fibrous cap   
 Infiltration of inflammatory cells.  
 
The lipid core is composed mainly by cholesterol and lipids remaining from dead foam 
cells (Davies, Richardson et al. 1993). Due to the rich presence of tissue factor 
produced by macrophages, this part of the lesion is extremely thrombogenic 
(Fernandez-Ortiz, Badimon et al. 1994). Autopsy studies have shown that lipid cores of 
ruptured plaques are larger in size than from non-ruptured (Virmani, Kolodgie et al. 
2000). From a biomechanical point of view a large soft lipid core is disadvantageous, 
unable to carry the mechanical forces, which instead are concentrated in the thin cap 
overlying the lesion, making it more vulnerable (Richardson, Davies et al. 1989).  
 
The cap covering the lesion consists of extra cellular matrix components such as, 
proteoglycans, collagen and elastin. There are few or no smooth muscle cells within the 
cap of a vulnerable plaque, the cap of carotid plaques have shown to have fewer 
macrophages than coronary plaques (Virmani, Kolodgie et al. 2000). The mean carotid 
cap thickness in plaque rupture (72±15 µm) is around three times as thick as in the 
coronary cap, which measures 23±19 µm near rupture sites and <65 µm for the other 
95% of the cap (Burke, Farb et al. 1997; Virmani, Kolodgie et al. 2000). The cap 
thickness is a net effect of the balance between matrix synthesis by smooth muscle cells 
and matrix degradation by metalloproteoases by inflammatory cells such as 
macrophages (Galis, Sukhova et al. 1994). 
 
Inflammatory cells present in the plaque are another hallmark of the classically defined 
plaque. Especially the numbers of present macrophages vastly outnumbers other cell 
types, such as T cells, neutrophils and mast cells. Macrophages infiltrating the fibrous 
cap are known to weaken the cap by secreting and activating matrix-degrading 
proteases. Compared to stable plaques, vulnerable plaques have been shown to contain 
abundant amounts of proteases (such as MMP-1, MMP-3 and MMP-9), these proteases 
are particularly active in the vulnerable regions of the plaque, such as the cap (Galis, 
Sukhova et al. 1994). Morover, neutrophils have also been associated with carotid 
plaque vulnerability (Ionita, van den Borne et al. 2010). 
 
In addition, neovascularization with intra-plaque bleedings is commonly observed.  
The importance of intraplaque hemorrhage (IPH) for plaque progression was elucidated 
in 2003 (Kolodgie, Gold et al. 2003). IPH was demonstrated to contribute to cholesterol 
deposition and macrophage infiltration, which in turn result in enlargement of the 
necrotic core. It was speculated that neovascularization of leaky microvessels in the 
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plaque could be responsible for the IPH. Later it was shown that an increased density of 
intimal leaky microvessels in the coronary lesion associate with vulnerable plaques 
(Sluimer, Kolodgie et al. 2009). This also holds true in carotid plaques, where 
vascularity correlates with IPH and presence of symptoms (Mofidi, Crotty et al. 2001). 
The leakiness is due to compromised integrity of the endothelium of the microvessels. 
 
1.1.4 The vulnerable patient 
Knowing that the vulnerable plaques are not the only culprit factors for developing 
cardiovascular events Naghavi et al. published a consensus statement in 2003, 
suggesting a new term for identification of patients being at risk of having an event in 
the near future, “the vulnerable patient”. The term “vulnerable patient” takes additional 
factors besides the vulnerable culprit lesion into account when estimating outcome, 
such as the vulnerable blood prone to thrombosis and the vulnerable myocardium, 
(Naghavi, Libby et al. 2003). The consensus document encouraged translational 
research for the identification and treatment of vulnerable patients, resulting in 
numerous studies trying to identify biomarkers. 
 
1.2 TOOLS TO IDENTIFY VULNERABILITY  
1.2.1 Biomarkers 
A biomarker is defined as a “characteristic that is objectively measured and evaluated 
as an indicator of normal biologic processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention”(2001). The ultimate goal when studying a 
biomarker, whether the marker is used to screen for disease, diagnose a disease, inform 
about prognosis or guide treatment response, is that it should affect clinical 
management. 
 
In CVD, cholesterol markers for cardiovascular events have been thoroughly 
investigated due to the crucial role of lipids in the development of atherosclerosis, 
unfortunately, the prognostic value of these markers is low since more than half of 
CVD events occur in patients with normal cholesterol levels (Ridker, Rifai et al. 2002). 
Many other potential biomarkers are shown to be quite unstable, one example being 
lipoprotein-associated phospholipase A2 (Lp-PLA2). Since Lp-PLA2 serum levels falls 
significantly after a stroke or a MI it is considered to be less robust for long term risk 
stratification shortly after primary events (Elkind, Leon et al. 2009). Contrary to 
LpPLA2, the serum levels of the myofibrillar protein troponin is rising after having an 
MI and is considered to be one of the most valuable standard diagnostic markers in 
clinical use. Assays for high sensitivity cardiac troponin have improved the early 
diagnostic accuracy for acute myocardial infarction as well as assessment of risk 
outcomes for acute coronary syndromes (Scirica 2010; Christenson and Phillips 2011).  
 
Another biomarker that has gained a lot of attention is C-reactive protein (CRP), a 
marker of ongoing inflammation. CRP has been shown to be a predictive marker for 
cardiovascular events among healthy people and add to the Framingham risk score 
(Ridker, Rifai et al. 2002). Based on the famous JUPITER (Justification for the Use of 
Statins in Primary Prevention) trial statins were demonstrated to be beneficial even in 
the absence of hyperlipidemia, resulting in lowered CRP and a significant decrease in 
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cardiovascular events (Ridker, Danielson et al. 2009). CRP is thought controversial 
since it is not specific for atherosclerosis and is upregulated during most infections and 
other inflammatory diseases, such as rheumatoid arthritis (Anderson, Caplan et al. 
2012).  
 
Non- invasive and invasive imaging of plaques has also been investigated to identify 
patients at risk. Although ongoing improvements have been made for imaging, there 
are still apparent limitations. One example of this is that many potentially dangerous 
vulnerable plaques tend to associate with compensatory remodeling, making current 
available imaging techniques impossible to base a clinical decision on (Pasterkamp, 
Schoneveld et al. 1998). The PROSPECT (Providing Regional Observations to Study 
Predictors of Events in the Coronary Tree) a prospective plaque imaging study 
followed the natural history of plaques throughout the coronary tree for the occurrence 
of future cardiovascular events and concluded that acute coronary syndromes often 
occurred at sites of mild coronary artery stenosis and did not necessarily have to 
involve luminal narrowing (Stone, Maehara et al. 2011). However, lesion-related risk 
factors for such events are poorly understood. Taken together, the continuous search for 
identification of markers of plaque instability is important. Table I summarizes the 
main desirable features of a good biomarker in atherosclerotic disease: 
 
 
Table I. Optimal features of a good biomarker 
 
All Biomarkers Biomarkers for screening of 
Vulnerable CVD patients 
 Explicit for a specific disease  Known reference limits 
 Add to clinical assessment  Add to known risk score such as 
FRS 
 Sampling acceptable to the 
patient 
 Change in total risk as seen with 
AUC risk calculations 
 Correlation between change in 
marker and pathology 
 Change management of the patient 
 Stable product  
 Single measurement 
representative 
 
 Applicable to both genders, 
different ages and ethnicities 
 
 Replicated in separate cohort  
CVD: Cardiovascular Disease; FRS: Framingham Risk Score; AUC: Area Under the Curve. 
 
 
1.2.2 Biobanking 
Biobanks are organized resources of biological tissue specimens, which are linked with 
clinical characteristics and can either be population or disease based (Yuille, van 
Ommen et al. 2008). The Swedish Act on Biobanks (SF 2002:297) defines the concept 
“Biobank” as "biological material from one or several human beings collected and 
stored indefinitely or for a specified time and whose origin can be traced to the 
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human or humans from whom it originates". All patients participating are required to 
receive informed consent since its introduction in the Nuremberg Code after the 
World War II. Informed consent requires that the research subject should know “the 
nature, duration, and purpose of the experiment; the method and means by which it is to 
be conducted; all inconveniences and hazards reasonable to be expected; and the effects 
upon his health or person which may possibly come from his participation in the 
experiment” (http://ohsr.od.nih.gov.ezp-prod1.hul.harvard. edu/guidelines/ nuremberg. 
html). These requirements have later been supplemented in many variants of the 
Declaration of Helsinki.  
 
During the last decade the numbers of biobanks have increased significantly. In 
Sweden alone, it is estimated that total sample numbers stored are around 50-100 
million human samples, increasing with around 3-4 million samples per year. 
Handling of biological sample is covered by the Swedish Act on Biobanks, however, 
information that is gained during analysis is strictly regulated by other laws, such as 
Patientjournallagen (the Swedish Act of Medical Records), Personuppgiftslagen (the 
Swedish Act of Personal Information), Sekretesslagen (the Swedish Official Secrets 
Act) and Etiklagen (the Swedish Act on Ethics) (biobanks.se). 
 
Biobanks are an important resource for: 
 
 Identifying intricate mechanisms and patterns of complex disorders. Depending 
on the timing of collection of specimens, the biobanks open up an opportunity to 
study disease prior to, during and after, onset of disease at a molecular level.  
 Investigations of rare disorders 
 Validations of findings made in experimental models 
 
One of the most famous and first examples of a population based cardiovascular 
biobank is the Framingham Heart Study initiated in 1951(Dawber, Meadors et al. 
1951) Periodically monitoring and registering cases of CVD among the 28 000 
participating subjects gave rise to many novel insights behind the pathophysiology 
behind CVD and resulted in the Framingham risk score model for risk stratification 
of CVD (Dawber, Meadors et al. 1951). The model is in use and so far the best 
available risk model in clinical practice.  
 
Considering that atherosclerosis is a systemic disease (Libby, Ridker et al. 2002; 
Hansson 2005), one could speculate that local plaque characteristics represent plaque 
development in other sites of the vasculature tree (Vink, Schoneveld et al. 2001). 
Thus, lesions obtained during surgery might both help us to dissect the pathogenesis 
behind the disease and to investigate markers predictive for future cardiovascular 
events depending on the design of the study.   
 
1.2.3  Biobank of Karolinska Endarterectomies, BiKE 
In this thesis, three out of four papers are based on data from our Biobank of 
Karolinska Endarterectomies (BiKE). BiKE was established 2001 in collaboration 
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between the Experimental Cardiovascular Research Group and the Department of 
Vascular Surgery. BiKE holds blood samples and carotid lesions removed during 
carotid endarterectomy (CEA) on consecutive patients operated at the Karolinska 
Hospital. CEA is recommended for patients with severe and symptomatic lesions 
based on several clinical trials addressing benefits and risks in different groups of 
patients with this procedure (1991) (ECST 1998). In these trials the degree of stenosis 
was used as a factor to predict risk, therefore stenosis has been used in the clinic to 
select patients for surgery. As already mentioned, however, a growing body of evidence 
has suggested the morphology to play a greater role than size in predicting vulnerability 
and subsequent events (Fuster, Moreno et al. 2005). Patients with severe unilateral 
carotid stenosis, but without symptoms were also operated based on results from 
randomized trial (Halliday, Harrison et al. 2010).  
 
In addition to tissue samples BiKE contains gene expression profiles and a clinical 
database, which includes a broad range of clinical information about the patients, such 
as, medications, echogenicity, laboratory tests, antrophometric data and comorbidities. 
The clinical data can be linked to gene expression data for investigations. Moreover, 
follow-up data and genotype data for the patients have been collected (Folkersen, 
Persson et al. 2012). Currently BiKE contains around 400 lesions of which around 150 
have been subjected to gene expression microarrays. This large collaboration, that 
BiKE constitutes, has over the years generated several publications investigating 
different aspects of atherosclerosis. For further reading on these topics, see the Table 
II. 
 
Table II. Overview of all publications that use data from BiKE 
 
 
Authors 
 
Main target/finding 
 
Role of BiKE 
 
Qiu et al. 2006 5-LO and LTA4H 
associate with plaque 
vulnerability (Paper I) 
Essential role for all 
human expression data 
and IHC 
Tran et al. 2007 HSPG2 is reduced in 
human carotid lesions 
Central role as source of 
all immunostaining and 
gene expression material 
Mälarstig et al. 2008 IRF5 is expressed in the 
lesions and is effected by 
proximal SNPs 
Source of eQTL 
measurements 
Folkersen et al. 2009 Real-time PCR 
comparison with 
microarrays (Paper II) 
Central role as source for 
all gene expression data 
Folkersen et al. 2009 CAD risk phenotype and 
chromosome 9p21 
Central role together with 
other biobanks 
Olofsson et el 2009 Tnfsf4 is increased in 
murine atherosclerosis 
A role in human gene 
expression data together 
with other biobanks 
Ueland et el. 2009 DKK-1 levels in Plaque mRNA 
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atherosclerosis, 
mechanistic and clinical 
studies 
measurements supporting 
main data 
Breland et al. 2010 MCP-4 levels, increased 
in symptomatic carotid 
atherosclerosis 
In vitro plaque mRNA 
measurements supporting 
main data 
Diez et al. 2010 Theoretical overview of 
network analysis methods 
Methodology exemplified 
by using BiKE expression 
data 
Folkersen et al. 2010 Association of genetic risk 
variants 
Central role for all 
measurements 
Gabrielsen et al. 2010 TBXAS1 is increased in 
murine atherosclerosis and 
correlates with 
macrophage markers 
Major role on macrophage 
marker correlation 
Gertow et al. 2010 ALOX15B is investigated 
in human carotid 
atherosclerosis 
Central role as a source of 
all gene expression data 
C4D 2011 GWAS, identifying new 
risk SNPs for MI 
Finding expression 
quantitative trait loci 
effects (eQTL) of novel 
GWAS risk-SNPs 
Agardh et al. 2011 FABP4 associate with 
plaque vulnerability 
(Paper III) 
Central role as source of 
all expression data and 
IHC data 
Razuvaev et al. 2011 Investigation of 317 
known atherosclerotic 
genes 
Central role as source of 
all expression 
measurements 
Wang et al 2011 IGFs and IGF-binding 
proteins in human carotid 
atherosclerosis 
Central role as source of 
all gene expression data 
Folkersen et al. 2012 Prediction of ischemic 
events 
Central role as source of 
all gene expression 
measurements 
Paulsson-Berne et al. 
2012 
Commentary to Agardh et 
al. 2011 
 
 
5-LO: 5-Lipoxygenas; LTA4H: Leukotriene A4 Hydrolase; IHC: Immunohistochemistry; HSPG2: 
Heparan Sulphate Proteoglycan; IRF5: Interferon Regulatory Factor 5; CAD: Coronary Artery Disease; 
DKK-1: Dickkopf-related protein 1; MCP-4: Monocyte Chemoattractant Protein 4; TBXAS1: 
Thromboxane A Synthase 1, ALOX15B: Arachidonate 15-Lipoxygenase, GWAS: Genome wide 
Association Study; FABP4: Fatty Acid Binding Protein 4, IGF: Insulin Like Growth Factor; eQTL: 
Quantitative Trait Loci Effects; BiKE: Biobank of Karolinska Endarterectomies; SNP: Single Nucleotide 
Polymorphism. 
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1.2.4 OMICS 
The central dogma in molecular biology, going from DNA via RNA to protein, gives 
ample opportunities for investigations at several unique levels in the search for new 
biomarkers (Figure 2). Through the Human Genome Project, the full human genome 
was sequenced and by 2004 the estimated numbers of protein coding genes was around 
20 000-25 000 (2004). This revolution was accompanied by development of high-
throughput methods providing immense capability for analyzing large number of 
genes, whether being on DNA (genomics), RNA (transcriptomics) or protein level 
(proteomics). By using all these approaches, functional genomics aims to give a more 
complete picture how functions arise from the genome. The concept behind omics 
approaches is that a given biological system is best analyzed by looking at global 
profiles rather than individual gene level. Coming section will focus on transcriptomics 
as the papers in my thesis are mainly based on investigations of RNA.  
 
 
 
Figure 2. Biological systems can be analyzed by the help of OMICS: DNA by genomics, RNA by 
transcriptomics and proteins by proteomics. 
 
 
1.2.4.1  Transcriptomics 
The definition of a transcriptome is the relative expression level of all transcripts in a 
cell or tissue at a given time point. Over the past 35 years reverse transcription and 
sequencing have provided insight into the transcribed regions of the genome, going 
from the well-known ribosomal, transfer and messenger RNAs to more recently 
discovered non-coding classes such as small interfering RNA(siRNA) and 
microRNA(miRNA) (Li and Liu 2011). Despite that only around 25% of the human 
genome consists of protein-coding genes, there is evidence indicating that the greater 
part of the genome is transcribed to some sort of the mentioned RNA transcript 
(Birney, Stamatoyannopoulos et al. 2007). Regardless of whether the RNA is 
translated into protein or has direct RNA-based functions, it is the first step in 
realizing the information content of the genome making it a highly interesting target 
to investigate. 
 
Conversely to the genome, the transcriptome is extremely dynamic and varies 
depending on factors such as, cell type, developmental stage of the cell and surrounding 
milieu. Hence, expression profiling of the transcriptome gives a biological snap shot of 
the transcript levels in the cell at a particular time or condition. For this reason many 
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studies have analyzed the transcriptome as means to dissect complex molecular 
processes behind a disease. Typically, specimens from healthy and diseased patients are 
compared, or tissue biopsies are used to compare different stages and forms of a 
disease. In my thesis plaque tissue and circulating cells have been investigated for 
identification of new biomarkers of atherosclerotic disease. In our studies the 
monocytes and neutrophils turned out to be important cell types, therefor I will 
introduce them in the next section. 
 
1.3 RELEVANT TARGETS 
1.3.1 Immune Cells 
Immune cells are classified either as tissue residing or blood borne. The blood borne 
cells are further distinguished based on their histological appearance, either 
polymorphonuclear (PMN) or mononuclear (Figure 3). The PMNs constitute; 
neutrophils that phagocytize microbes during inflammation; eosinophils that participate 
during allergic and parasitic infections; and basophils involved in allergic reactions. 
Lymphocytes and monocytes instead make up the mononuclear cell compartment. 
Monocytes are recruited from the circulation during late stages of acute inflammation 
and during chronic inflammation, and differentiate into phagocytic macrophages in the 
extravascular tissue. Lymphocytes, T and B cells, are specialized cells of the adaptive 
immune system, T cells being important for antigen-specific responses and B cells for 
antibody production (Abbas & Lichtman, 2009). In my thesis there are above all two 
cell types of interest for our findings, neutrophils and the monocytes/macrophages. 
These will be briefly introduced in the sections below. 
 
 
 
 
Figure 3. Typical cell nucleus of a PMN neutrophil(left) and a mononuclear monocyte(right). 
 
 
1.3.2 Neutrophils 
Neutrophils are the most abundant leukocytes in the circulation and also one of the 
most short lived cell types, dying within a few hours of inflammatory initiation. They 
are usually associated with acute inflammation and are thus among the first to respond 
to tissue damage and invading microorganisms. They phagocytose and with the help of 
reactive oxygen species (ROS) they destroy microbes. In addition, the cytoplasm of the 
neutrophils is filled with different types of granules containing presynthesized 
enzymes, such as cytotoxic myeloperoxidase (MPO), elastases and matrix 
metalloproteases (MMPs). These will both be secreted and/or come into contact with 
the microbes upon formation of the phagosome. In addition, the neutrophils are 
predominant producers of inflammatory mediators called leukotrienes, known to 
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mediate inflammatory responses such as vasodilation, increased vascular permeability 
and further neutrophil recruitment (Haeggstrom and Funk 2011). 
 
1.3.3 Monocytes and Macrophages 
Monocytes originate from the bone marrow and constitute between 3 to 8% of all 
leukocytes in the circulation. In contrast to neutrophils they are long lived, typically 
present in the circulation for a couple of days before entering into tissues where they 
can differentiate into macrophages and undergo cell division. Macrophages respond 
nearly as fast as neutrophils to microbes. In addition to being a phagocytic cell, 
macrophages present antigens to lymphocytes /cells of the adaptive system and are 
producers of cytokines. Several subsets of both monocytes and macrophages have been 
identified during the last decade and can be divided into both pro- and anti-
inflammatory subsets based on their cytokine secretion and surface markers (Abbas & 
Lichtman). The classically activated macrophages (M1) are known to drive 
inflammation by secreting pro-inflammatory cytokines such as IL1, IL-6 and IL-12, 
whereas, it has been suggested that CD163 positive macrophages (M2) play a role in 
the resolution of inflammation. M2 are found in high number in inflamed tissues and 
are differentiated by mediators, such as IL-4 and IL-13 (M2a) or IL-10 (M2b) or LPS 
(M2c) (Sulahian, Hogger et al. 2000; Schaer, Boretti et al. 2002; Martinez, Sica et al. 
2008). For a simplified version of the subsets, see figure 4 below.  
 
 
 
 
Figure 4. Overview showing subsets of monocytes and macrophages. 
The murine inflammatory monocyte expresses Ly6C
high
, whereas the human counterpart expresses 
CD14
+
CD16
- 
. The murine anti-inflammatory, resident monocyte, express a lower level of Ly6C 
(human counterpart CD14
low
CD16
+
). The surrounding milieu effects the transition to either a pro-
inflammatory M1 macrophage or a wound healing, repairing M2 macrophage phenotype. Typically 
IFN-γ drives the differentiation into M1. M1 secretes pro-inflammatory cytokines such as, IL1β, IL-6 
and IL-12 as well as nitrogen reactive species (NRS). IL-4 and IL-13 instead pushes the monocyte into 
anti-inflammatory M2 phenotype expressing CD163. In addition to these, several other macrophage 
subsets have been found. The scavenger receptor CD36 are more highly expressed on M1 than on M2 
macrophages, whereas CD68 is present on both subtypes. 
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In addition to these two classical subsets of macrophages, several other populations 
have been described. The so called Mox macrophage was recently introduced, shown to 
be induced by oxidized phospholipids (Kadl, Meher et al. 2010). Thereafter the M4 
macrophage was found displaying a different transcriptome to the classically described 
M1 and M2 macrophages, and showed lower expression of scavenger receptors plus 
increased levels of cholesterol efflux (Gleissner, Shaked et al. 2010). These subsets are 
probably not the last ones to be introduced in the macrophage field. 
 
1.3.4 Fatty acid binding proteins 
Fatty acid binding proteins (FABPs) are a family of, so far, nine identified proteins 
(Smathers and Petersen 2011) of which the first member was found in 1972 (Ockner, 
Manning et al. 1972). The members were historically regarded to be tissue specific 
therefore their names derive from their site of expression. However, this nomenclature 
is slightly misleading due to the fact that the different family members were later 
shown to be present at several locations. Subsequently an extra numerical nomenclature 
was added (Storch and Thumser 2010) (see Table III). Furthermore, the expression of 
the FABPs in a given cell type seems to reflect the cells lipid-metabolizing capacity. In 
for example adipocytes and cardiomyocytes, where fatty acids are prominent for lipid 
biosynthesis, storage or breakdown, the FABP can make up between 1-5% of all 
soluble proteins. The amount of FABPs in the cells can be further increased during 
times of increased fatty acid exposure (Veerkamp and van Moerkerk 1993).  
 
All FABPs members are 14-15kDa in size and localized in the cytoplasm of the cell, 
where their major function is to act as a lipid chaperon, reversibly binding and 
trafficking a quite broad range of  lipids throughout cellular compartments (Smathers 
and Petersen 2011). Studies using experimental models have demonstrated FABPs to 
play a central role in lipid mediated processes, affecting metabolic and immune 
response pathways. However, their regulation, their exact biological function(s) and 
mechanism of action is still poorly understood.  
 
The sequence diversity between the members of FABPs is great, sharing from only 15 
up to 70% similarity. Although, structurally they are extremely conserved and consist 
of ten stranded anti-parallel beta sheets which form a beta barrel surrounding a water-
filled interior binding pocket. In addition, two alpha helices cap the pocket and regulate 
the binding of ligands (Chmurzynska 2006). The family is evolutionary conserved and 
present in a spectrum of species including Caenorhabditis elegans, Drosophila 
melanogaster, mouse and humans (Furuhashi and Hotamisligil 2008). 
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Table III Members of the human fatty acid binding family 
Common Name Gene Expression Sites 
Liver FABP Fabp1 Liver, intestine, pancreas, kidney, lung, stomach 
Intestinal FABP Fabp2 Intestine, liver 
Heart FABP Fabp3 Heart, skeletal muscle, brain, kidney, lung, stomach, 
testis, aorta, adrenal gland, placenta, ovary, brown 
adipose tissue 
Adipocyte FABP Fabp4 Adipocyte, macrophage, dendritic cell, endothelial cell 
Epidermal FABP Fabp5 Skin, tongue, adipocyte, macrophage, dendritic cell, 
mammary gland, brain, intestine, kidney, liver, lung, 
heart, skeletal muscle, testis, retina, lens, spleen 
Ileal FABP Fabp6 Ileum, ovary, adrenal, gland, stomach 
Brain FABP Fabp7 Brain, glial cell, retina, mammary gland 
Myelin FABP Fabp8 Peripheral nervous system, Schwann cell 
Testis FABP Fabp9 Testis, salivary gland, mammary gland 
Modified from Nature Reviews, Furuhashi et al.2008 June;7:489-503. 
 
1.3.4.1 Fatty Acid Binding Protein 4  
Adipocyte fatty acid binding protein or FABP4 was originally found in adipocytes.  
The cytosolic protein makes up about 1-3% of total cytosolic protein content in 
adipocytes and is up-regulated around 50 times during the adipocyte differentiation 
process (Reese-Wagoner, Thompson et al. 1999). Later the protein has been identified 
in macrophages (Makowski, Boord et al. 2001), foam cells (Fu, Luo et al. 2002), 
dendritic cells (Rolph, Young et al. 2006) and endothelial cells (Elmasri, Karaaslan et 
al. 2009). Still the exact biological function of FABP4 is unknown. 
 
The gene for FABP4 is located on chromosome 8q21human (3A1 in mice) and is 
transcriptionally regulated by trans-acting nuclear factors and cis-acting regulatory 
elements in the 5’ flanking region. The TATA box is located 31 base pairs upstream of 
the transcription start site and two fat-specific elements (FSE) are found within the 
gene. Further upstream of the flanking region of FABP4 there are five adipocyte 
regulatory elements (ARE1, ARE2, ARE4, ARE6 and ARE7). Interestingly, around 5.5 
kb upstream of the transcription site, FABP4 also comprise peroxisome proliferator 
response elements (PPREs), which allow for transcriptional regulation by fatty acids, 
insulin and PPARɣ agonists.  
 
 
1.3.4.2 FABP4 in Atherosclerosis 
Animal studies have shown that FABP4 is strongly linked to atherosclerotic plaque 
development. Crossing Apoe
-/- 
with a knockout of FABP4, Ap2
-/-
 resulted in a greatly 
reduced lesion size with or without high fat diet (Makowski, Boord et al. 2001) 
(Perrella, Pellacani et al. 2001). In addition, bone marrow transplantation (BMT) 
showed a comparable reduction in lesion size, indicating a role for FABP4 in 
macrophages during atherogenesis. These results highlight a separate action of FABP4 
from adipocytes and provide a link between metabolic syndrome and atherosclerosis. 
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Macrophages lacking FABP4 also show a significant decrease of cholesterol 
accumulation and decreased level of secreted cytokines TNF-α, Il-1β and IL-6 upon 
exposure to lipoproteins (Makowski, Boord et al. 2001). Moreover, it has been shown 
that using an orally active small-molecule inhibitor of FABP4 effectively reduces 
atherosclerosis without effecting body weight, lipid or glucose metabolism in Apoe
-/- 
(Furuhashi, Tuncman et al. 2007). 
 
One of the first studies implying relevance of FABP4 in human atherosclerosis was 
observed in vitro when FABP4 was upregulated during differentiation of human THP-1 
cells to foam cells (Fu, Luo et al. 2002).Thereafter, studies investigating the expression 
in human plaques are lacking until our own study was published in 2011. In addition, 
the role of FABP4 in the serum has recently being intensively investigated, even though 
it is not known whether this free form has any functional role. Serum concentration of 
FABP4 has been associated in the CVD field with factors such as carotid intima-media 
thickness in women (Yeung, Xu et al. 2007) and coronary plaque burden (Miyoshi, 
Onoue et al. 2010). In line with this, one of the 5 SNP variants (T-87C) identified in 
Caucasians leading to decreased expression, has been associated with reduced risk for 
coronary artery disease in a population cohort of around 8000 carriers (Tuncman, Erbay 
et al. 2006).  
 
1.3.5 Leukotrienes 
Leukotrienes (LTs) were first discovered in leukocytes, as indicated by their name, and 
are primarily formed in granulocytes, monocytes/macrophages, mast cells, and 
dendritic cells (Samuelsson 1979). In 1976 a great discovery was made at Karolinska 
Institute, showing the 5-lipoxygenase (5-LO) pathway for arachidonic acid (AA) 
metabolism in rabbit leukocytes (Borgeat, Hamberg et al. 1976) and subsequent studies 
identified leukotriene B4 (LTB4) to be the major product of the 5-LO pathway(Borgeat 
and Samuelsson 1979). The AA derivates are known to mediate inflammatory 
responses such as vasodilation, vascular permeability and neutrophil recruitment and 
are predominantly made by PMNs and mast cells (Funk 2001). 
 
1.3.5.1 The 5-LO pathway  
Expression of the enzyme 5-LO is essentially restricted to cells derived from the bone 
marrow such as, neutrophils, monocytes/macrophages, mast cells, dendritic cells and B 
cells (Radmark and Samuelsson 2007). Upon cell activation and LT biosynthesis, 5-LO 
will translocate from the cytosol to the nuclear envelope in a calcium dependent 
manner (Chen and Funk 2001) (Figure 5). Upregulation of the 5-LO protein has been 
shown during GM-CSF stimulation of human neutrophils (Pouliot, McDonald et al. 
1994). Assistance of the enzyme 5-leukotriene activating protein (FLAP) seems to 
facilitate the interaction between 5-LO and AA (Mancini, Abramovitz et al. 1993) and 
to increase the efficiency in which 5-LO converts 5-hydroxyperoxy eicosatetraenoic 
acid (5-HPETE) into leukotriene A4 (LTA4) (Abramovitz, Wong et al. 1993). 
Thereafter leukotriene A4 hydrolase (LTA4H), present in most cells, catalyzes the 
hydrolysis of the unstable LTA4 into LTB4 (Haeggstrom and Funk 2011). LTB4 are 
known to bind, with high and low affinity to the BLT1 and BLT2 receptors 
respectively, that are present on leukocytes and when stimulated cause degranulation 
and chemotaxis (Tager and Luster 2003).  
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Figure 5. The leukotriene 5-LO pathway 
Following activation, arachidonic acid (AA) is liberated from cPLA2 and converted to LTA4 by 5-
lipoxygenase (5-LO) and 5-lipoxygenase activating protein (FLAP) via 5-hydroxyperoxy 
eicosatetraenoic acid (5-HPETE). LTA4 is then converted to LTB4 by LTA4 hydrolase and to LTC4 by 
LTC4 synthase which is further converted to LTD4 and LTE4. Adapted from: Clinical Asthma, Castro 
& Kraft, 2005. 
 
Alternatively to form LTB4, LTA4 can be conjoined with glutathione to form LTC4 in 
turn yielding LTD4 and LTE4. These leukotrienes are collectively called cysteinyl 
leukotrienes and are known for their slow and sustained muscle contracting abilities. 
The cysteinyl leukotrienes bind to the Cys-LT1 and Cys-LT2 receptors that are 
present on airway smooth muscle cells and vascular endothelial cells(Funk 2001), and 
are known as potent inducers of increased vascular permeability(Dahlen, Bjork et al. 
1981).  
 
1.3.5.2  5-LO and Atherosclerosis 
Several interesting studies regarding 5-LO in experimental and human atherosclerosis 
came out starting from year 2002, highlighting a potential important role for this 
pathway in disease progression. In Ldlr
-/-
 mice crossed with 5-lo
-/+
 a dramatic reduction 
of lesion development was observed (Mehrabian, Allayee et al. 2002) and in human 
atherosclerotic lesions abundant level of 5-LO was demonstrated at different stages of 
disease (Spanbroek, Grabner et al. 2003). Additionally, genetic studies from Iceland 
convincingly showed polymorphisms in the 5-LO promoter to associate with an 
increased atherosclerosis (Dwyer, Allayee et al. 2004), and the gene encoding FLAP to 
augment the risk for MI and stroke (Helgadottir, Manolescu et al. 2004). However, later 
publications from work in mouse models have yielded inconclusive results, for 
example in Apoe 
-/-
 x 5-lo
-/-
 only a minor atheroprotective effect was shown (Poeckel 
and Funk 2010). 
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2 AIMS OF THIS THESIS 
The common objective for all studies performed within this thesis has been to 
investigate the inflammatory genes involved during different stages of human and 
murine atherosclerotic lesion development. More specifically the aims were to: 
 
 
 Investigate atherosclerotic plaque levels of the 5-LO leukotriene pathway, both 
in human vulnerable plaques and in murine plaques   
 
 Determine optimal normalization method for real-time PCR in complex carotid 
tissue for transcript evaluation  
 
 Analyze the gene expression profile of human atherosclerotic plaques linked to 
clinical data, to identify potential biomarkers of plaque vulnerability 
 
 Investigate possible biomarkers in circulating leukocytes reflecting progression 
of murine atherosclerotic lesions  
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3 METHODOLOGICAL CONSIDERATIONS 
3.1 HUMAN SPECIMENS 
The papers included in my thesis have all been conducted at least in some parts on 
human tissue samples including; atherosclerotic carotid lesions obtained during carotid 
endarterectomies (paper I, II, III), iliac arteries obtained from transplant donors 
(paper I) and blood cells obtained from healthy donors (paper III and IV).  
 
3.1.1 Biobank of Karolinska Endarterectomies, BiKE 
The BiKE biobank was established in 2001. The database consists of clinical data, 
plasma samples and atherosclerotic lesion removed during carotid endarterectomy 
(CEA) on consecutive patients operated at Karolinska Hospital. Removed carotid 
plaques were immediately rinsed with sterile PBS in the operation theatre and cut 
transversely over the most prominent region of the plaque. Three quarters of the 
specimen is frozen on dry ice for later isolation of RNA and one quarter, for 
morphological analyses, is embedded in OCT and stored in -80ᵒC.   
 
Patient undergoing surgery usually present with symptoms such as minor stroke, 
transient ischemic attacks (TIA) or amaurosis fugax. In cases of more than 70 % 
stenosis of the carotid artery, as detected with ultrasonography, CEA is recommended. 
In addition, CEA is also recommended in asymptomatic men with narrowing of the 
carotid artery. The North American Symptomatic Carotid Endarterectomy Trial 
(NASCET) criteria were used for selection. In paper III, patients with atrial fibrillation 
was excluded from the data set, as their emboli causing symptoms might be of cardiac 
origin. 
 
In paper I, a major concern was the use of suitable controls to the carotid lesions. A 
contra-lateral healthy artery would obviously have been an optimal normal control, but 
this is for obvious reasons not an option. Instead we had to settle with the best we could 
get, which in this case were iliac arteries from transplant donors. The adventitia and 
outer media of the arteries were removed before freezing. In addition, the vessels were 
macroscopically analyzed and excluded if signs of intimal thickening were apparent. In 
paper III, we based our investigation solely on endarterectomies and could thus avoid 
this discussion. 
 
3.2 MURINE MODELS OF ATHEROSCLEROSIS 
Murine models of atherosclerosis are the most commonly used experimental models for 
studying the processes that underlie the pathogenesis of atherosclerosis. There are 
several advantages with this approach. Mice are relatively cheap, have short 
reproducibility time with large litters and are genetically well-defined. Even before the 
era of transgenic technology, it was known that most mice strains are resistant to 
atherosclerosis even after feeding with an atherosclerotic diet. The C57BL/6 mouse, 
which is the standard background of all mice strains used in this thesis, is an exception 
and develops small fatty streaks when fed atherosclerotic diet. With the technique of 
genetic engineering several models of atherosclerosis prone mice strains were made 
available. The most commonly used today are the apolipoprotein E (Apoe
-
/
-
) knock out 
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mouse and the LDL-receptor (Ldlr
-
/
-
) knock out mouse. In addition, these two knock 
out models have been crossed in order to give rise to an even more susceptible disease 
model (Hemdahl, Gabrielsen et al. 2006). 
Even though murine models give the opportunity to dissect the different molecular 
pathways during development of advanced plaques, there are some major limitations 
that should be kept in mind when performing translational studies. The experimental 
murine models very seldom develop plaque rupture with thrombosis, which is one of 
the main clinical manifestations in humans. Furthermore, the cholesterol levels in mice 
necessary for plaque development goes far beyond concentrations encountered in 
humans. In addition, the murine immune system deviates from that of humans (Libby, 
Ridker et al. 2011).  
 
3.2.1 Apoe-/- mice (paper I, IV) 
Apoe
-
/
-
 mice were created in 1992 by homologous recombination in embryonic stem 
cells (Plump, Smith et al. 1992; Zhang, Reddick et al. 1992). Due to the lack of ApoE, 
needed for clearance of lipoproteins by the liver, the strain develops severe 
hypercholesterolemia even under normal dietary conditions. The aortic plaques develop 
rapidly from initial fatty streaks to more complex lesions strikingly similar to those in 
humans, both in phenotype and distribution. Predilection sites for atherosclerotic 
lesions in Apoe
-
/
-
 mice are the aortic root, followed by the aortic arch, the 
brachiocephalic trunk, the left carotid, and subclavian and coronary 
arteries(Nakashima, Plump et al. 1994) (Bentzon and Falk 2010). One disadvantage 
with the Apoe
-
/
-
 model is that the lipoprotein profile deviates from humans. Whereas 
LDL is the major carrier of cholesterol in the circulation, the murine lipid profile is 
dominated by augmented levels of VLDL. Another drawback with this knock out 
model is that the role ApoE plays in other processes, such as immune activation, is lost 
(Tenger and Zhou 2003). 
 
3.2.2 Apoe-/- x Ldlr -/- mice (paper I) 
The Ldlr
−
/
−
 strain instead have a plasma lipid profile resembling that of humans. The 
knock out of the receptor affects the clearance of VLDL and LDL from plasma. As a 
result, the mice will develop atherosclerosis then fed a diet high in fat and cholesterol 
(Knowles and Maeda 2000). In addition, the Ldlr
−
/
−
 strain has been crossed with Apoe
-
/
-
 
rendering a strain which develops severe hyperlipidemia and atherosclerosis on chow 
diet.  This model has been proposed suitable to study the anti-atherosclerotic effect of 
compounds without having to feed the animals an atherogenic diet (Bonthu, Heistad et 
al. 1997).  
 
3.3 RNA EXPRESSION ANALYSIS 
Quantifying gene expression by traditional DNA methods, such as Northern blot or 
Southern Blot can be quite crude and will not allow to precise quantification. In all 
papers included in my thesis gene expression analysis has been made by using the more 
modern techniques, real-time PCR and microarrays. In the following sections I will 
introduce these two different methods.  
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3.3.1 Real-time PCR (paper I, II, III, IV) 
Polymerase chain reaction (PCR) is a powerful technique used to amplify segment of 
DNA by using oligonucleotides (flanking primers) in a series of reactions catalyzed 
by a DNA-polymerase in the presence of the four dNTPs (Saiki, Gelfand et al. 1988). 
In 1993 the first attempt was made to monitor amplification of PCR products in real-
time, using a video camera and inclusion of ethidiumbromide in the PCR mixture 
(Higuchi, Fockler et al. 1993). The emitted fluorescence was found to be proportional 
to the amount of product formed. A cycle number where the fluorescent signal 
exceeded the background signal (called "cycle threshold", CT-value) were identified 
and could be used to calculate starting material in a sample. Real-time PCR 
revolutionized the RNA expression analysis of single gene targets by collecting data 
during real-time.  
 
We are using real-time PCR to investigate different levels of mRNA expression in 
different tissues. Briefly, the method is based on sequence specific DNA probes 
labeled with a fluorescent reporter dye in combination with primers.  First RNA is 
reversely transcribed to cDNA with reverse transcriptase, before adding real-time 
PCR probe and primers. As the reaction starts the primers and the probes will anneal 
to the cDNA. From the primers, polymerisation of a new DNA strand will be initiated 
with help of Taq DNA polymerase. When the polymerase reaches the probe, which 
contains both a quencher and a fluorescent reporter at the opposite end, a fluorescent 
signal will be emitted due to physical separation of the quencher and the reporter. The 
fluorescence is measured and the exponential increase is used to analyze the threshold 
cycle. 
 
3.3.2 Microarrays (paper I, II, III, IV) 
In mRNA or microarray gene expression profiling experiment, the expression of 
thousands of genes is simultaneously measured to study and identify gene transcription 
level during for example pathogenesis of different diseases, developmental stages or 
efficacy of certain treatments. The microarray technology was evolved from the 
Southern blotting principle, where fragmented DNA is probed with a known fragment 
or gene. The early microarrays were first described in 1987 and consisted of cDNA 
spotted onto filter paper (Kulesh, Clive et al. 1987). Since then several different types 
of arrays have been developed, all based on a common mechanism, namely the 
hybridization of a sample of unknown labeled RNA sequences to a set of known 
sequences located on the array, so called oligonucleotides. Fluorescently labeled 
sequences that bind to a probe sequence will generate a signal, which then will be 
scanned and translated to a quantitative parameter for the RNA at the specific position 
(Figure 6). Depending on the type of array used, several steps such as reverse 
transcription, amplifications and/or fragmentations steps before the hybridization might 
be performed. There are also differences in the sequence length of the probes, as well 
as organization of the probes within the gene.  
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Figure 6. Overview – RNA to microarray analysis 
RNA is isolated, reversely transcribed to cDNA subsequently biotin labeled and then allowed to 
hybridize to the microarray containing short oligonucleotides from known reference sequences. Finally, 
the array is scanned with a laser scanner and analyzed. 
 
3.3.2.1 Microarrays from Affymetrix 
The microarrays used in Paper II, III and IV are all from Affymetrix; 
 
Paper II:  Human Genome U133 Plus 2.0; 
Paper III: Human Genome U133A  
Paper IV:  Mouse Genome MOE430A.  
 
These microarrays use probe sets, consisting of groups with between 4 to13 of 25 
nucleotides long probe sequences, which only matches one specific region in the gene. 
The different probes in a set are in turn grouped to match genomic locations in close 
proximity to each other. For an overview of number of transcripts/genes possible to 
analyze, see table IV below.  
 
 
Table IV Overview of microarrays included in paper II, III and IV 
 HGU133 plus 2.0 HGU133A MOE430A 
Transcripts (n) ~47 400 ~18 400  
Genes (n) >38 500 >14 500 ~14 000 
Probe sets (n) >54 000 >22 000 >22 600 
Feature size (um) 11 8 8 
Oligonucleotide probe length 25 25 25 
Probe pairs/sequence 11 11 11 
HGU- Human Genome; MOE: Mouse Genome 
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3.4 IMMUNOHISTOCHEMISTRY (PAPER I, III, IV) 
We have analyzed different proteins of interest by using immunohistochemistry. A 
general protocol for enzymatic staining visualized with light microscopy has been used 
in paper I and III. Immunohistochemistry is based on detection of a specific antigen 
by a primary antibody followed by incubation of a secondary, biotinylated antibody, 
which recognizes regions of the first antibody.  Thereafter enzyme-conjugated 
streptavidin molecules are incubated on the section forming a complex with the bound 
biotin. By adding a substrate, the enzymatic activity of the bound will form a color 
precipitate at the sites of antigen-antibody binding. The most crucial of this method is 
the use of good quality antibodies with high antigen specificity. Another important 
aspect of this method is the use of proper controls. There are many different discussions 
about this topic. In paper I we have been using blocking peptides to ascertain the 
specificity of the primary antibodies. In papers III and IV we take use of isotype 
controls not recognizing any proteins in the sample of interest, but generated in the 
same species as the antibody recognizing the protein of interest. In addition one should 
try every step of the staining procedure, and each new batch of primary and secondary 
antibodies, to exclude false positive staining. In addition, it is helpful to counterstain 
specimens with a nuclear stain to be able to identify cells from staining artifacts. In 
papers I, III and IV we have used fluorescent double labeling for simultaneous 
detection of two antigens in the same specimen. The principle is the same as for 
detecting proteins with enzymatic staining, the difference is that the secondary antibody 
is either directly conjugated with a fluorochrome or the streptavidin molecules are 
conjugated with a fluorochrome.  Similarly, controls are crucial to determine whether 
the same signal for each individual antibody is obtained both in the single and the 
double staining step. To counterstain the nuclei I have used the dye DAPI (4', 6-
diamidino-2-phenylindole), which binds to AT-rich regions in DNA and stains the 
nuclei blue. Lipids and structural components in atherosclerotic lesions cause 
autofluoresence which may affect the detection of specific signals severely. We have 
managed to partly quench the autofluoresence signals by incubating the sections with 
Sudan Black allowing for successful use of fluorescent staining in the lesion. In paper 
I we are using fluorescence microscopy with different filter cubes to analyze our 
stainings and in paper III and IV I have been using confocal microscopy. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I- 5-LO PATHWAY IN CAROTID PLAQUE INSTABILITY 
Leukotrienes (LTs) belong to a family of lipid mediators and are involved in host 
defense and inflammatory responses. Furthermore, LTs have been found to be involved 
in both human and experimental atherogenesis (Mehrabian, Allayee et al. 2002; 
Spanbroek, Grabner et al. 2003). In humans the 5-lipoxygenase pathway has previously 
been shown to be expressed in the vessel wall of patients with various stages of 
atherosclerotic lesions in the carotid and coronary arteries (Spanbroek, Grabner et al. 
2003). In paper I we aimed at investigating plaque levels and more specifically 
vulnerability in relation to three key enzymes in the LTB4-biosynthesis, namely 5-
lipoxygenase (5-LO), 5-LO activating protein (FLAP), and LTA4 hydrolase. 
Furthermore, the levels of these enzymes were investigated in atherosclerotic murine 
models, the Apoe
-
/
-
 and the double knockout Ldlr
-
/
- 
x Apoe
-
/
-
. 
 
We show that the human carotid lesions reveal high transcript levels of 5-LO, FLAP 
and LTA4H as compared to control iliac arteries, confirming previous data on human 
atherosclerotic specimen (Spanbroek, Grabner et al. 2003). In addition, staining of the 
plaques demonstrate abundant expression of 5-LO, FLAP and LTA4H in the intima, 
co-localizing with the macrophage marker CD163. All three enzymes have a similar 
distribution throughout the plaque, indicating a possible degree of co-expression in the 
cells, presumably facilitating enzyme coupling and LTB4 production.  
 
In agreement with our finding, macrophages represent a major source for LTB4 
(Haeggstrom and Funk 2011). In addition, previous research has shown LTB4 to be a 
strong chemotactic agent influencing major events involved throughout the 
atherosclerotic lesion progression, such as recruitment of inflammatory T cells and 
monocytes both via chemotaxis and effects on adhesion molecules(Friedrich, Tager et 
al. 2003). Moreover, LTB4 increase the expression of MCP-1 which in turn enhances 
further monocyte recruitment (Huang, Zhao et al. 2004). This may create a vicious 
circle to further recruit and drive the inflammatory response in the atherosclerotic 
lesion, eventually leading to plaque vulnerability. Consistent with this hypothesis, the 
mRNA levels of 5-LO and LTA4H in the atherosclerotic plaques correlate to the 
occurrence of clinical symptoms. Interestingly, both 5-LO and LTA4H are significantly 
higher in patients with recent clinical symptoms of TIA, minor stroke and/or amaurosis 
fugax (see Figure 7). This is independent of plasma cholesterol levels, gender, or 
treatment with statins or angiotensin-converting enzyme inhibitors. However, FLAP 
did not associate with clinical symptoms, suggesting the existence of an additional 
regulatory mechanism. 
 
Ruptured plaques causing symptoms will eventually heal (Virmani, Kolodgie et al. 
2005). The time between the last recorded symptom (<1 month, 1-3 months and >3 
months) and the endarterectomy presumably represents plaques at different stages of 
instability. Combining our data, showing the association of 5-LO and LTA4H mRNA 
to plaque vulnerability, and previous Icelandic studies showing 5-LO and LTA4H to 
be risk factors for atherosclerosis (Dwyer, Allayee et al. 2004) (Helgadottir, 
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Manolescu et al. 2004), strongly suggest LTB4 to be involved in local inflammatory 
processes that precede vulnerability and clinical symptoms. 
 
 
 
Figure 7: Correlation of 5-LO, FLAP, and LTA4H mRNA levels with clinical symptoms. 
Levels of 5-LO, FLAP, and LTA4H mRNA in human carotid plaques were correlated with the 
occurrence of symptoms of plaque instability. The mRNA levels of 5-LO and LTA4H were 
significantly higher in patients with symptoms within 1 month (n = 18) than in patients with the last 
symptoms >3 months ago (n=10). Data are presented as mean ± SD, *, P < 0.05; **, P < 0.01; ***, P 
< 0.001 (as compared with iliaca). 
 
Moreover, we demonstrate that homogenate of human plaque indeed produce 
significant amounts of LTB4 when incubated with arachidonic acid. This synthesis is 
dampened by 80% after pre-incubation with the selective and tight-binding inhibitor of 
LTA4H, aminohydroxamic acid inhibitor (figure 8). Thus LTA4H, the enzyme that 
catalyzes LTB4-production, could be a potential good drug target for stabilizing the 
plaque and preventing associated complications. 
 
 
 
 
Figure 8. Synthesis of LTB4 in human carotid plaque and inhibition by an LTA4H inhibitor. 
Homogenates of human plaque tissue (n=8) were preincubated for 30 min in the absence (n=4) or 
presence (n=4) of a hydroxamic acid inhibitor of LTA4H (HA) followed by incubation with 
arachidonic acid. LTB4 was measured by HPLC-EIA, and data are presented as mean ±SD. **, P 
<0.01 
 
Importantly, our finding in human atherosclerotic lesions with respect to expression 
pattern of the proteins in the 5-LO LT-pathway shows profound differences to the 
murine situation. In murine aortic plaques from Apoe
-
/
-
 and the Ldlr
-
/
- 
x Apoe
-
/
-
 we 
show the levels of 5-LO, FLAP and LTA4H to be essentially the same except for 
LTA4H, which is being up-regulated in the double knock out. Staining of 5-LO and 
LTA4H show the enzymes to distribute in different localizations of the murine plaque, 
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with 5-LO being present in the adventitia and LTA4H being present in the intima. In 
addition, analysis of the LT cysteinyl receptor CysLT1 show a 2.5 to 3 times fold 
upregulation in Apoe
-
/
-
 and the Ldlr
-
/
- 
x Apoe
-
/
- 
as compared with control mice. 
Immunostaining demonstrate the CysLT1 receptor to colocalize with CD68 in the 
murine lesion. Also the CysLT2 receptor is upregulated 3 times in the Apoe
-
/
-
 as 
compared to control. These receptors did not differ in level between human carotid 
plaques as compared to controls. 
   
 
 
Several factors could be the reasons for this observed species difference. The human 
atherosclerotic plaques used in this study are from advanced stages causing clinical 
symptoms after decades of progression, whereas the murine lesions are less advanced. 
Although much knowledge has been achieved with the use of murine models, it is 
essential to keep in mind that the mice do not develop signs of plaque rupture and 
symptoms. Moreover, the multiple factors operating in initiation of disease as 
compared to the ones in destabilization are also likely to differ.  
 
4.2 PAPER II- ENDOGENOUS CONTROL GENES IN CAROTID LESIONS  
When determining mRNA levels in different specimens and cell line experiments, a 
commonly used and sensitive method is real-time PCR. The relative quantification of 
mRNA is usually determined by normalizing to endogenous controls, so called 
housekeeping genes (HKGs), to correct for amount of RNA starting material and for 
efficiency in the cDNA synthesis(Livak and Schmittgen 2001).  
 
In paper II we wanted to investigate how different choices of endogenous controls 
would affect the real-time PCR results. To perform this we take advantage of the 
possibility to correlate our measurements to another method for measuring mRNA, 
namely the microarrays. In addition, we wanted to compare these two different 
methods used for expression analysis. The samples we are investigating are human 
carotid lesions from our biobank, BiKE. These tissue samples are quite heterogeneous, 
consisting of a various degree of inflammatory cells, smooth muscle cells and 
endothelial cells. Thus, the proportion between the cell types will vary between 
different samples. 
 
We selected 5 endogenous control genes based on the available set of 10 HKGs from 
Applied Biosystems. In addition to the direct measurement of these 5 HKGs, we 
calculated the stability index using all combinations of two or more of the 5 HKGs. 
This was done to test the recommendation by Vandesompele et al. (Vandesompele, De 
Preter et al. 2002) that multiples of HKGs are beneficial to real-time PCR 
normalization.  
 
Real-time PCR for 15 different genes normalized with the 5 controls or combinations 
were compared with probe sets from microarray expression data. For all different 
combinations Pearson correlations were calculated to be able to compare; 1) 
correlations between different genes and; 2) differences in correlations depending on 
the choice of using either an endogenous control, combinations of endogenous controls 
or no endogenous control. We demonstrate that some, but not all, genes show a good 
correlation between real-time PCR measurements and microarrays. Furthermore, we 
demonstrate that the best correlation between microarray data and real-time PCR is 
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obtained when only normalizing real-time PCR to the initial amount of RNA material 
used – the no endogenous control situation. 
 
The reasons for non-corresponding genes can be due to systematic technical as well as 
biological factors.  One technical factor we could identify was a coefficient of variance 
of duplicate real-time PCR measurements. If this was below 0.02, there was no 
correspondence between microarray and real-time PCR data. In spite of thorough 
quality control of other technical aspects of real-time PCR and microarray, we could 
not explain all non-corresponding genes. Another interesting aspect that could explain 
difference in measurements is alternative splicing and difference in probe location for 
the two measurements. In our setting the probe locations were different for all except 4 
genes. This opens up speculation that alternative-splicing could theoretically be the 
reason for the remaining non-corresponding genes. However, further measurements of 
concurrent exonic locations would have been required to support such a claim. Instead 
we focused on the difference in HKGs-dependent correspondence between microarray 
and real-time-PCR measurements. Our results showed that there was a better 
correspondence between the two methods when real-time PCR is normalized to the 
amount of initial RNA- i.e. without the use of endogenous controls.  
 
A useful formal definition of gene expression is that it is units of mRNA per cell. This 
is the level at which changes will affect the biology of a cell. To reach this definition, 
the methods we compare must therefore be based on one of three assumptions: 
 
1) There exists one or more genes for which the expression is at sufficiently 
constant level to be proportional to the amount of cells across the sample (for 
real-time PCR, using endogenous controls) 
2) The overall distribution of the expression levels of all genes is the same in all 
cells and across all samples (for microarray using the RMA-algorithm) 
3) Total concentration of RNA is the same in all cells across all samples (for 
normalization to total RNA mass). This carries the assumption based on that the 
reverse transcription from RNA to cDNA is equally efficient. 
  
It seems likely, that the first assumption is very hard to satisfy in tissue sample of 
mixed cell populations. We therefore conclude that introduction of HKGs may perturb 
the data without improving measurements in complex heterogeneous tissues, such as 
carotid plaques. This is in line with a previous study that speculated that normalizing to 
total RNA mass will be better in complex tissue (Qin, Beyer et al. 2006). In addition, 
we see advantages with the microarrays having the total gene expression profile to 
normalize against, arguing a more robust data normalization-wise as compared to real-
time PCR. Nonetheless normalization using HKG is still the golden standard, therefore 
in coming paper III and IV we take use of this method. 
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4.3 PAPER III- CAROTID PLAQUE VULNERABILITY ASSOCIATE WITH 
FABP4  
Accumulation of lipids and ongoing inflammation are hallmarks of the vulnerable 
plaque and play essential roles in the pathogenesis of atherosclerosis (Virmani, 
Kolodgie et al. 2000). The lipid core of a vulnerable plaque is demonstrated to be large, 
infiltrated by inflammatory cells and covered by a thin cap (Corti, Hutter et al. 2004). 
Within the first few days after a transient ischemic attack the risk of a stroke is 
increased. This risk is reduced if a CEA is performed soon after the occurrence of 
symptoms (Giles and Rothwell 2006). Plaques which have ruptured and caused 
symptoms may also heal and show regression of inflammation (Sacco, Adams et al. 
2006).  
 
The time aspects mentioned above make up the basis for our investigation in paper III 
where we base plaque vulnerability on time between last recorded symptom and CEA. 
By the use of microarray technology we compared the transcriptomes of the 
atherosclerotic lesion between asymptomatic patients and symptomatic patients with 
symptoms less or more than 1 month ago, revealing FABP4 mRNA to be more 
abundant in vulnerable plaques. This was confirmed using real-time RT-PCR (see 
Figure 9). The patient groups differed with regard to gender and age, however, the level 
of FABP4 in the lesion did importantly not associate with any of these factors. Thus, 
FABP4 turns out to be a potentially attractive biomarker for predicting plaque 
vulnerability and applicable for investigated ages and both genders.  
 
 
 
 
 
 
Figure 9. Expression of FABP4 mRNA in carotid endarterectomies. FABP4⁄ aP2 mRNA 
expression as determined by real-time quantitative RT-PCR in carotid endarterectomies. Comparison 
between asymptomatic patients, patients with symptoms within 1 month and those experiencing 
symptoms more than 1 month ago. Symptoms of plaque instability are defined as transient ischemic 
attacks, minor stroke and/or amaurosisfugax. mRNA levels were normalized to cyclophilinA mRNA 
expression in each sample. *P = 0.01 
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At the time of our finding, studies had implicated FABP4 to integrate the inflammatory 
and lipid-mediated pathways. The lipid binding protein had moreover been considered 
to play an essential role in plaque progression as investigated in experimental models 
(Makowski, Boord et al. 2001; Perrella, Pellacani et al. 2001; Boord, Maeda et al. 2002; 
Makowski, Brittingham et al. 2005).  However, studies investigating FABP4 in human 
atherosclerotic lesions were lacking, making our study highly relevant. 
 
Along with association to plaque vulnerability we observe the level of FABP4 mRNA 
within atherosclerotic endarterectomies to correlate with markers of macrophages 
supporting our initial finding (Figure 10). Specifically good correlation was seen with 
the markers CD36, CD68 and CD163 in the plaque. Our observation is in line with a 
previous study made in a human THP-1 macrophage cell line, where FABP4 correlated 
with foam cell development (Fu, Luo et al. 2002). The same group also observed 
FABP4 to be related with increased inflammatory activity (Makowski, Brittingham et 
al. 2005). Moreover, an inverse correlation was observed between FABP4 and smooth 
muscle cells, giving further evidence for linking FABP4 to unstable plaque phenotype, 
as unstable plaques usually display a thin cap with fewer SMCs (Burke, Farb et al. 
1997). 
 
 
Figure 10. Correlations between FABP4 and different cells markers at mRNA level in BiKE, within 
the atherosclerotic lesion as extracted from microarrays. Plots show the correlation between FABP4 and 
macrophages (CD36, CD68 and CD163) and vascular smooth  muscle cells (-actin). Pearson correlation 
*** p<0.001  
 
To identify cell types expressing FABP4 and to  localize the protein in the plaque, we 
performed immunohistochemistry and could clearly show FABP4 to be localized in 
macrophages (CD36, CD68 and CD163 positive cells). FABP4 was present both in the 
cytoplasm and the nuclei of the cells. From our study we cannot draw any conclusions 
whether FABP4 is more abundant in the pro-inflammatory macrophage phenotype 
M1or the healing macrophage phenotype M2 or Mox. FABP4 was also shown to be 
present in some endothelial cells. Furthermore, we observe an association of FABP4 
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and T cells on mRNA level. The association between these markers reflects increased 
number of inflammatory cells in advanced plaques, as we did not observe any FABP4 
in the T cells.  
 
In addition to an association between FABP4 and CD36, FABP4 associates with the 
enzymes 5-LO and LTA4H involved in LTB4 production. LTA4H is soluble and does 
not translocate to the nuclear membrane, transfer of LTA4 from 5-LO to LTA4H seems 
to require a carrier stabilizing the molecule, which presumably could involve FABP 
(Zimmer, Dyckes et al. 2004). LTB4 in turn has been shown to enhance expression of 
CD36 (Subbarao, Jala et al. 2004) leading to increased foam cell formation. 
Interestingly, FABP4 also associated with adipophilin, previously shown to be 
increased at both RNA and protein level in symptomatic carotid plaques (Nuotio, 
Isoviita et al. 2007).  
 
Adipophilin is an adipose differentiation-related protein expressed in lipid-containing 
cells, shown to participate in foam cell formation in vitro (Robenek, Buers et al. 2009) 
and  suggested to play an inflammatory role in macrophages in vivo (Chen, Yang et al. 
2010). The association between adipophilin and FABP4 might therefore reflect 
increased foam cell formation in the plaque, but a direct interaction between FABP4 
and adipophilin is to date unknown. Taken together, our data strengthens a complex 
relation between FABP4, leukotrienes, foam cell formation and plaque vulnerability.  
 
In conclusion, our data show FABP4 to be upregulated in symptomatic plaques as 
compared to asymptomatic ones. This is in line with experimental data implying 
FABP4 to play a major role in atherosclerotic progression and to contribute in plaque 
destabilization. Our study has later been confirmed by three other groups demonstrating 
FABP4 to correlate with plaque instability in three independent cohorts (Peeters, de 
Kleijn et al. 2010; Holm, Ueland et al. 2011; Saksi, Ijas et al. 2011). 
 
4.4 PAPER IV- FABP4 IN LEUKOCYTES ASSOCIATE WITH LESION 
PROGRESSION 
In paper III we identified FABP4 to be augmented within the lesion in unstable plaque 
phenotypes, which have given rise to symptoms. Although this finding is exciting the 
plaque per se is quite impractical to access for measuring biomarkers. Moreover it 
would be beneficial to identify asymptomatic patients at risk of having an event in the 
near future, before the actual event. We hypothesized that circulating cells might 
contain potential biomarkers reflecting the disease progression due to the fact that 
atherosclerosis is a systemic inflammatory disease. Hence, the purpose of paper IV 
was to analyze gene expression profiles in circulating cells during atherosclerotic 
disease progression. To investigate this we used the well-defined experimental 
atherosclerotic Apoe
-
/
-
 model, where lesion progression from early fatty streaks to more 
advanced plaques can be studied. 
 
By unbiased approach using Affymetrix microarrays, we identify FABP4 mRNA in 
circulating cells to associate with lesion progression (Figure 11). FABP4 has, as 
previously mentioned, been shown to play an important role in experimental models of 
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atherosclerosis. To our knowledge this is the first time that the intracellular level of 
FABP4 in circulating leukocytes has been reported to reflect extent of disease. 
 
 
 
 
Figure 11. Level of FABP4 mRNA in circulating leukocytes correlates with extent of 
atherosclerotic lesion in aorta.  mRNA levels of FABP4 in circulating leukocytes from Apoe
-
/
-
 (12, 20 
and 32 weeks of age) measured by RT-PCR TaqMan and correlated to percentage of lesion size (r= 
0.800, ***p<0.0001) (n=22). 
 
Using ELISA we confirm our finding of FABP4 within the leukocytes on protein level 
(Figure 12). Importantly the plasma level of FABP4 protein did not change with 
disease progression, indicating FABP4 to be an attractive biomarker for atherosclerosis 
specifically within the leukocytes. 
 
 
 
 
Figure 12. FABP4 protein level increases in circulating leukocytes in Apoe
-
/
-
 with disease 
progression but is stable in plasma. Intracellular protein level in circulating leukocytes of FABP4 in 
Apoe
-
/
-
 (10-11, 20-22 and 35-37 weeks of age female) as measured by ELISA (n=7-8 per group). FABP4 
concentrations in plasma in Apoe
-
/
-
 (10-11, 20-22 and 35-37 weeks of age) as measured by ELISA (n=7-8 
per group). ***P<0.0001 vs. Apoe
-
/
-
 20w, *P<0.05 vs. Apoe
-
/
-
 32w. ns indicates not significant. 
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Interestingly, we demonstrate FABP4 to be mainly expressed by Ly6G-positive 
neutrophils in the circulation. Total neutrophil numbers in the murine model are stable 
throughout the ages investigated, implying that the increase seen is not linked with 
changes in specific leukocyte populations. Neutrophils per se have not until recently 
been thought to play a major role in atherosclerosis progression (Zernecke, Bot et al. 
2008). One recent study showed the neutrophils to constitute 2% of all infiltrated 
leukocytes in the shoulder region of the murine plaque (Rotzius, Thams et al. 2010). 
We show FABP4 positive neutrophils to be localized to the subendothelial space and 
shoulder regions within the murine plaque. 
 
Inflammatory Ly6C
Hi
 monocytes are robustly recruited to the atherosclerotic lesion. In 
our study Ly6C
Hi 
dominates over the less inflammatory Ly6C
low
 monocyte population 
in the circulation at less advanced stages of disease (age 12 and 20 weeks of age). 
During the time of early fatty streak formation (age 12 weeks of age in Apoe
-/-
 mice) 
cholesterol levels are twice as high as observed at later stages. Our observations support 
a previous study, showing hypercholesterolemia to increase the Ly6C
Hi
 population 
(Swirski, Libby et al. 2007). Although, at 20 weeks of age when the cholesterol level 
drops by half the Ly6C
Hi
 population still dominates in the circulation, suggesting 
additional other factors in the inflammatory milieu to drive this subset. Due to technical 
issues we could not stain Ly6C together with FABP4. However, in the circulation 
FABP4 is localized to some extent in monocytes expressing CD68 and in the lesion 
FABP4 is more strongly expressed by some of these cells. This is in line with in vitro 
data showing increased levels of FABP4 during foam cell formation.  
 
Finally, we investigate localization of FABP4 in leukocytes from human healthy 
donors, to see whether our finding could be of relevance for further investigations in 
carotid atherosclerotic patients. Indeed, we see similar expression pattern, localizing 
FABP4 to both monocytes and neutrophils (Figure 13).  
 
 
 
 
Figure 13. Co-localization of FABP4 to human neutrophils and monocytes  
Human leukocytes were stained with FABP4 (green) and the neutrophil marker CD66b (A) or the 
monocyte marker CD14 (B). Nuclei stained blue with DAPI, as seen in the small imbedded photos in the 
left hand corner of A and B. White bar 5µm. 
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In conclusion, our results imply a role for FABP4 in the circulating leukocytes as a 
biomarker reflecting extent of atherosclerosis in an experimental model. This finding 
needs to be further investigated in human atherosclerotic patients. 
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5 CONCLUDING REMARKS 
It is generally acknowledged that atherosclerosis is an inflammatory systemic disease 
of the arteries. Numerous ongoing investigations are trying to dissect and understand 
the complex processes behind lesion development. Although some classical risk factors 
have been established during the last decades, there is still a need for finding and 
validating new possible biomarkers involved in the pathogenesis for better 
identification of vulnerable plaques and vulnerable patients at risk in the near future.  
Combination of clinical samples and experimental models, as seen in this thesis, is 
essential to cover different aspects and stages of disease. My aim was to identify genes 
involved in the pathogenesis of human as well as experimental atherosclerosis.  
 
In paper I we showed that mRNA of enzymes involved in LTB4-production, 5-LO and 
LTA4H, associated with plaque vulnerability in humans. Thus, suggesting a critical 
role of LTB4 during clinically significant stages of atherosclerosis. We conclude that 
LTA4H, the terminal enzyme in LTB4-synthesis, could be a potential pharmacological 
target for amelioration of atherosclerotic complications. 
 
In paper II we compared real-time PCR and microarrays and tested different 
normalization methods of real-time PCR for correlations to microarrays. We conclude 
that normalization to total RNA mass in complex heterogeneous tissues might be better 
than using housekeeping genes. However, since the latter is standard we chose to use 
this normalization method in paper III and IV. 
 
In paper III we demonstrated an increased mRNA level of FABP4 in human 
symptomatic plaques as compared to asymptomatic plaques. In addition we localized 
FABP4 to macrophages within the lesions. In line with paper I, mRNA of FABP4 
associated with the enzymes 5-LO and LTA4H. We conclude that FABP4 is involved 
in processes leading to plaque vulnerability and could be an interesting target in future 
therapeutics. 
  
In paper IV we investigated if mRNA in circulating cells could reflect atherosclerotic 
lesion progression in the atherosclerotic Apoe
-/-
 model and found FABP4 expressed in 
neutrophils and monocytes to be a promising candidate. We conclude that FABP4 in 
circulating cells is of future interest to investigate in human atherosclerosis. 
 
The papers presented in this thesis demonstrate that FABP4 is a player in processes 
involved in atherosclerosis, both within human plaque reflecting vulnerability and in 
circulating leukocytes in Apoe
-/-
 reflecting extent of atherosclerotic plaque progression. 
Although, the exact mechanism of action still is to be unraveled. In addition to 
associate with plaque vulnerability, FABP4 also associates with the enzymes 5-LO and 
LTA4H, enzymes of the leukotriene pathway resulting in LTB4 production. The fact 
that all these proteins constitute markers for vulnerability makes them interesting for 
further clinical investigations for identification and/or amelioration of plaque 
vulnerability. Another attractive approach for identification of atherosclerotic disease 
progression could potentially be to measure the level of FABP4 in circulating 
leukocytes. Even though our findings need further investigations to be translated into 
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clinic practice, I hope that these studies included in my thesis have shared some light on 
these potential markers involved in the atherosclerotic disease process. 
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